Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

A clonal expression biomarker associates with lung cancer mortality.

Biswas D, Birkbak NJ, Rosenthal R, Hiley CT, Lim EL, Papp K, Boeing S, Krzystanek M, Djureinovic D, La Fleur L, Greco M, Döme B, Fillinger J, Brunnström H, Wu Y, Moore DA, Skrzypski M, Abbosh C, Litchfield K, Al Bakir M, Watkins TBK, Veeriah S, Wilson GA, Jamal-Hanjani M, Moldvay J, Botling J, Chinnaiyan AM, Micke P, Hackshaw A, Bartek J, Csabai I, Szallasi Z, Herrero J, McGranahan N, Swanton C; TRACERx Consortium.

Nat Med. 2019 Oct 7. doi: 10.1038/s41591-019-0595-z. [Epub ahead of print]

PMID:
31591602
2.

Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC.

Graf W, Cashin PH, Ghanipour L, Enblad M, Botling J, Terman A, Birgisson H.

Ann Surg Oncol. 2019 Sep 30. doi: 10.1245/s10434-019-07452-2. [Epub ahead of print]

PMID:
31571052
3.

c-MET as a biomarker in patients with surgically resected non-small cell lung cancer.

Tsakonas G, Botling J, Micke P, Rivard C, LaFleur L, Mattsson J, Boyle T, Hirsch FR, Ekman S.

Lung Cancer. 2019 Jul;133:69-74. doi: 10.1016/j.lungcan.2019.04.028. Epub 2019 May 1.

PMID:
31200831
4.

Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.

La Fleur L, Falk-Sörqvist E, Smeds P, Berglund A, Sundström M, Mattsson JS, Brandén E, Koyi H, Isaksson J, Brunnström H, Nilsson M, Micke P, Moens L, Botling J.

Lung Cancer. 2019 Apr;130:50-58. doi: 10.1016/j.lungcan.2019.01.003. Epub 2019 Jan 9.

5.

Mucin staining is of limited value in addition to basic immunohistochemical analyses in the diagnostics of non-small cell lung cancer.

Micke P, Botling J, Mattsson JSM, Planck M, Tran L, Vidarsdottir H, Nodin B, Jirström K, Brunnström H.

Sci Rep. 2019 Feb 4;9(1):1319. doi: 10.1038/s41598-018-37722-0.

6.

LMO7 and LIMCH1 interact with LRIG proteins in lung cancer, with prognostic implications for early-stage disease.

Karlsson T, Kvarnbrink S, Holmlund C, Botling J, Micke P, Henriksson R, Johansson M, Hedman H.

Lung Cancer. 2018 Nov;125:174-184. doi: 10.1016/j.lungcan.2018.09.017. Epub 2018 Sep 24.

PMID:
30429017
7.

Immunohistochemical profiles in primary lung cancers and epithelial pulmonary metastases.

Vidarsdottir H, Tran L, Nodin B, Jirström K, Planck M, Jönsson P, Mattsson JSM, Botling J, Micke P, Brunnström H.

Hum Pathol. 2019 Feb;84:221-230. doi: 10.1016/j.humpath.2018.10.009. Epub 2018 Oct 31.

PMID:
30389437
8.

Comparison of Three Different TTF-1 Clones in Resected Primary Lung Cancer and Epithelial Pulmonary Metastases.

Vidarsdottir H, Tran L, Nodin B, Jirström K, Planck M, Mattsson JSM, Botling J, Micke P, Jönsson P, Brunnström H.

Am J Clin Pathol. 2018 Oct 24;150(6):533-544. doi: 10.1093/ajcp/aqy083.

PMID:
30169783
9.

PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.

Tsao MS, Kerr KM, Kockx M, Beasley MB, Borczuk AC, Botling J, Bubendorf L, Chirieac L, Chen G, Chou TY, Chung JH, Dacic S, Lantuejoul S, Mino-Kenudson M, Moreira AL, Nicholson AG, Noguchi M, Pelosi G, Poleri C, Russell PA, Sauter J, Thunnissen E, Wistuba I, Yu H, Wynes MW, Pintilie M, Yatabe Y, Hirsch FR.

J Thorac Oncol. 2018 Sep;13(9):1302-1311. doi: 10.1016/j.jtho.2018.05.013. Epub 2018 May 22.

10.

Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer.

La Fleur L, Boura VF, Alexeyenko A, Berglund A, Pontén V, Mattsson JSM, Djureinovic D, Persson J, Brunnström H, Isaksson J, Brandén E, Koyi H, Micke P, Karlsson MCI, Botling J.

Int J Cancer. 2018 Apr 18. doi: 10.1002/ijc.31545. [Epub ahead of print]

11.

Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung.

Nicholson AG, Torkko K, Viola P, Duhig E, Geisinger K, Borczuk AC, Hiroshima K, Tsao MS, Warth A, Lantuejoul S, Russell PA, Thunnissen E, Marchevsky A, Mino-Kenudson M, Beasley MB, Botling J, Dacic S, Yatabe Y, Noguchi M, Travis WD, Kerr K, Hirsch FR, Chirieac LR, Wistuba II, Moreira A, Chung JH, Chou TY, Bubendorf L, Chen G, Pelosi G, Poleri C, Detterbeck FC, Franklin WA.

J Thorac Oncol. 2018 Feb;13(2):205-217. doi: 10.1016/j.jtho.2017.10.019. Epub 2017 Nov 7.

12.

RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer.

Rao S, Sigl V, Wimmer RA, Novatchkova M, Jais A, Wagner G, Handschuh S, Uribesalgo I, Hagelkruys A, Kozieradzki I, Tortola L, Nitsch R, Cronin SJ, Orthofer M, Branstetter D, Canon J, Rossi J, D'Arcangelo M, Botling J, Micke P, Fleur L, Edlund K, Bergqvist M, Ekman S, Lendl T, Popper H, Takayanagi H, Kenner L, Hirsch FR, Dougall W, Penninger JM.

Genes Dev. 2017 Oct 15;31(20):2099-2112. doi: 10.1101/gad.304162.117. Epub 2017 Nov 8.

13.

Integrative analysis of genome-wide gene copy number changes and gene expression in non-small cell lung cancer.

Jabs V, Edlund K, König H, Grinberg M, Madjar K, Rahnenführer J, Ekman S, Bergkvist M, Holmberg L, Ickstadt K, Botling J, Hengstler JG, Micke P.

PLoS One. 2017 Nov 7;12(11):e0187246. doi: 10.1371/journal.pone.0187246. eCollection 2017.

14.

Serotonin, ATRX, and DAXX Expression in Pituitary Adenomas: Markers in the Differential Diagnosis of Neuroendocrine Tumors of the Sellar Region.

Casar-Borota O, Botling J, Granberg D, Stigare J, Wikström J, Boldt HB, Kristensen BW, Pontén F, Trouillas J.

Am J Surg Pathol. 2017 Sep;41(9):1238-1246. doi: 10.1097/PAS.0000000000000908.

PMID:
28719461
15.

Gene Expression Profiling of Large Cell Lung Cancer Links Transcriptional Phenotypes to the New Histological WHO 2015 Classification.

Karlsson A, Brunnström H, Micke P, Veerla S, Mattsson J, La Fleur L, Botling J, Jönsson M, Reuterswärd C, Planck M, Staaf J.

J Thorac Oncol. 2017 Aug;12(8):1257-1267. doi: 10.1016/j.jtho.2017.05.008. Epub 2017 May 20.

16.

Immune Biomarkers on the Radar-Comprehensive "Immunograms" for Multimodal Treatment Prediction.

Botling J, Sandelin M.

J Thorac Oncol. 2017 May;12(5):770-772. doi: 10.1016/j.jtho.2017.03.009. No abstract available.

17.

Reaching the limits of prognostication in non-small cell lung cancer: an optimized biomarker panel fails to outperform clinical parameters.

Grinberg M, Djureinovic D, Brunnström HR, Mattsson JS, Edlund K, Hengstler JG, La Fleur L, Ekman S, Koyi H, Branden E, Ståhle E, Jirström K, Tracy DK, Pontén F, Botling J, Rahnenführer J, Micke P.

Mod Pathol. 2017 Jul;30(7):964-977. doi: 10.1038/modpathol.2017.14. Epub 2017 Mar 10.

18.

Somatic Ephrin Receptor Mutations Are Associated with Metastasis in Primary Colorectal Cancer.

Mathot L, Kundu S, Ljungström V, Svedlund J, Moens L, Adlerteg T, Falk-Sörqvist E, Rendo V, Bellomo C, Mayrhofer M, Cortina C, Sundström M, Micke P, Botling J, Isaksson A, Moustakas A, Batlle E, Birgisson H, Glimelius B, Nilsson M, Sjöblom T.

Cancer Res. 2017 Apr 1;77(7):1730-1740. doi: 10.1158/0008-5472.CAN-16-1921. Epub 2017 Jan 20.

19.

The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases.

Thunnissen E, Borczuk AC, Flieder DB, Witte B, Beasley MB, Chung JH, Dacic S, Lantuejoul S, Russell PA, den Bakker M, Botling J, Brambilla E, de Cuba E, Geisinger KR, Hiroshima K, Marchevsky AM, Minami Y, Moreira A, Nicholson AG, Yoshida A, Tsao MS, Warth A, Duhig E, Chen G, Matsuno Y, Travis WD, Butnor K, Cooper W, Mino-Kenudson M, Motoi N, Poleri C, Pelosi G, Kerr K, Aisner SC, Ishikawa Y, Buettner RH, Keino N, Yatabe Y, Noguchi M.

J Thorac Oncol. 2017 Feb;12(2):334-346. doi: 10.1016/j.jtho.2016.12.004. Epub 2016 Dec 18.

20.

The Human Adrenal Gland Proteome Defined by Transcriptomics and Antibody-Based Profiling.

Bergman J, Botling J, Fagerberg L, Hallström BM, Djureinovic D, Uhlén M, Pontén F.

Endocrinology. 2017 Feb 1;158(2):239-251. doi: 10.1210/en.2016-1758.

PMID:
27901589
21.

Various Antibody Clones of Napsin A, Thyroid Transcription Factor 1, and p40 and Comparisons With Cytokeratin 5 and p63 in Histopathologic Diagnostics of Non-Small Cell Lung Carcinoma.

Tran L, Mattsson JS, Nodin B, Jönsson P, Planck M, Jirström K, Botling J, Micke P, Brunnström H.

Appl Immunohistochem Mol Morphol. 2016 Oct;24(9):648-659.

PMID:
26447895
22.

Profiling cancer testis antigens in non-small-cell lung cancer.

Djureinovic D, Hallström BM, Horie M, Mattsson JSM, La Fleur L, Fagerberg L, Brunnström H, Lindskog C, Madjar K, Rahnenführer J, Ekman S, Ståhle E, Koyi H, Brandén E, Edlund K, Hengstler JG, Lambe M, Saito A, Botling J, Pontén F, Uhlén M, Micke P.

JCI Insight. 2016 Jul 7;1(10):e86837. doi: 10.1172/jci.insight.86837.

23.

Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer.

Mattsson JS, Brunnström H, Jabs V, Edlund K, Jirström K, Mindus S, la Fleur L, Pontén F, Karlsson MG, Karlsson C, Koyi H, Brandén E, Botling J, Helenius G, Micke P, Svensson MA.

BMC Cancer. 2016 Aug 5;16:603. doi: 10.1186/s12885-016-2646-x.

24.

The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs.

Micke P, Mattsson JS, Djureinovic D, Nodin B, Jirström K, Tran L, Jönsson P, Planck M, Botling J, Brunnström H.

J Thorac Oncol. 2016 Jun;11(6):862-72. doi: 10.1016/j.jtho.2016.01.020. Epub 2016 Feb 9.

25.

The protein kinase LKB1 negatively regulates bone morphogenetic protein receptor signaling.

Raja E, Tzavlaki K, Vuilleumier R, Edlund K, Kahata K, Zieba A, Morén A, Watanabe Y, Voytyuk I, Botling J, Söderberg O, Micke P, Pyrowolakis G, Heldin CH, Moustakas A.

Oncotarget. 2016 Jan 12;7(2):1120-43. doi: 10.18632/oncotarget.6683.

26.

Identification of sample annotation errors in gene expression datasets.

Lohr M, Hellwig B, Edlund K, Mattsson JS, Botling J, Schmidt M, Hengstler JG, Micke P, Rahnenführer J.

Arch Toxicol. 2015 Dec;89(12):2265-72. doi: 10.1007/s00204-015-1632-4. Epub 2015 Nov 25.

27.

HaloPlex Targeted Resequencing for Mutation Detection in Clinical Formalin-Fixed, Paraffin-Embedded Tumor Samples.

Moens LN, Falk-Sörqvist E, Ljungström V, Mattsson J, Sundström M, La Fleur L, Mathot L, Micke P, Nilsson M, Botling J.

J Mol Diagn. 2015 Nov;17(6):729-39. doi: 10.1016/j.jmoldx.2015.06.009. Epub 2015 Sep 3.

PMID:
26354930
28.

Novel somatic mutations and distinct molecular signature in aldosterone-producing adenomas.

Åkerström T, Willenberg HS, Cupisti K, Ip J, Backman S, Moser A, Maharjan R, Robinson B, Iwen KA, Dralle H, D Volpe C, Bäckdahl M, Botling J, Stålberg P, Westin G, Walz MK, Lehnert H, Sidhu S, Zedenius J, Björklund P, Hellman P.

Endocr Relat Cancer. 2015 Oct;22(5):735-44. doi: 10.1530/ERC-15-0321.

PMID:
26285814
29.

Oligonucleotide gap-fill ligation for mutation detection and sequencing in situ.

Mignardi M, Mezger A, Qian X, La Fleur L, Botling J, Larsson C, Nilsson M.

Nucleic Acids Res. 2015 Dec 15;43(22):e151. doi: 10.1093/nar/gkv772. Epub 2015 Aug 3.

30.

Comprehensive genomic profiles of small cell lung cancer.

George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan NS, Park KS, Yang D, Karnezis AN, Vaka D, Torres A, Wang MS, Korbel JO, Menon R, Chun SM, Kim D, Wilkerson M, Hayes N, Engelmann D, Pützer B, Bos M, Michels S, Vlasic I, Seidel D, Pinther B, Schaub P, Becker C, Altmüller J, Yokota J, Kohno T, Iwakawa R, Tsuta K, Noguchi M, Muley T, Hoffmann H, Schnabel PA, Petersen I, Chen Y, Soltermann A, Tischler V, Choi CM, Kim YH, Massion PP, Zou Y, Jovanovic D, Kontic M, Wright GM, Russell PA, Solomon B, Koch I, Lindner M, Muscarella LA, la Torre A, Field JK, Jakopovic M, Knezevic J, Castaños-Vélez E, Roz L, Pastorino U, Brustugun OT, Lund-Iversen M, Thunnissen E, Köhler J, Schuler M, Botling J, Sandelin M, Sanchez-Cespedes M, Salvesen HB, Achter V, Lang U, Bogus M, Schneider PM, Zander T, Ansén S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt C, Perner S, Heukamp L, Büttner R, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK.

Nature. 2015 Aug 6;524(7563):47-53. doi: 10.1038/nature14664. Epub 2015 Jul 13.

31.

Patients with Non-small Cell Lung Cancer Analyzed for EGFR: Adherence to Guidelines, Prevalence and Outcome.

Sandelin M, Berglund A, Sundström M, Micke P, Ekman S, Bergqvist M, Bergström S, Koyi H, Brandén E, Janson C, Botling J.

Anticancer Res. 2015 Jul;35(7):3979-85.

PMID:
26124345
32.

Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer.

Birgisson H, Edlund K, Wallin U, Påhlman L, Kultima HG, Mayrhofer M, Micke P, Isaksson A, Botling J, Glimelius B, Sundström M.

BMC Cancer. 2015 Mar 14;15:125. doi: 10.1186/s12885-015-1144-x.

33.

LRIG1 is a prognostic biomarker in non-small cell lung cancer.

Kvarnbrink S, Karlsson T, Edlund K, Botling J, Lindquist D, Jirström K, Micke P, Henriksson R, Johansson M, Hedman H.

Acta Oncol. 2015;54(8):1113-9. doi: 10.3109/0284186X.2015.1021427. Epub 2015 Mar 27.

PMID:
25813475
34.

Prognostic impact of COX-2 in non-small cell lung cancer: a comprehensive compartment-specific evaluation of tumor and stromal cell expression.

Mattsson JS, Bergman B, Grinberg M, Edlund K, Marincevic M, Jirström K, Pontén F, Hengstler JG, Rahnenführer J, Karlsson MG, Karlsson C, Helenius G, Botling J, Micke P, Gulyas M.

Cancer Lett. 2015 Jan 28;356(2 Pt B):837-45. doi: 10.1016/j.canlet.2014.10.032. Epub 2014 Oct 31.

PMID:
25449785
35.

1p36 deletion is a marker for tumour dissemination in microsatellite stable stage II-III colon cancer.

Mayrhofer M, Kultima HG, Birgisson H, Sundström M, Mathot L, Edlund K, Viklund B, Sjöblom T, Botling J, Micke P, Påhlman L, Glimelius B, Isaksson A.

BMC Cancer. 2014 Nov 24;14:872. doi: 10.1186/1471-2407-14-872.

36.

Genomic and transcriptional alterations in lung adenocarcinoma in relation to smoking history.

Karlsson A, Ringnér M, Lauss M, Botling J, Micke P, Planck M, Staaf J.

Clin Cancer Res. 2014 Sep 15;20(18):4912-24. doi: 10.1158/1078-0432.CCR-14-0246. Epub 2014 Jul 18.

37.

An integrative analysis of the tumorigenic role of TAZ in human non-small cell lung cancer.

Noguchi S, Saito A, Horie M, Mikami Y, Suzuki HI, Morishita Y, Ohshima M, Abiko Y, Mattsson JS, König H, Lohr M, Edlund K, Botling J, Micke P, Nagase T.

Clin Cancer Res. 2014 Sep 1;20(17):4660-72. doi: 10.1158/1078-0432.CCR-13-3328. Epub 2014 Jun 20.

38.

Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.

Micke P, Mattsson JS, Edlund K, Lohr M, Jirström K, Berglund A, Botling J, Rahnenfuehrer J, Marincevic M, Pontén F, Ekman S, Hengstler J, Wöll S, Sahin U, Türeci O.

Int J Cancer. 2014 Nov 1;135(9):2206-14. doi: 10.1002/ijc.28857. Epub 2014 Apr 8.

39.

In situ mutation detection and visualization of intratumor heterogeneity for cancer research and diagnostics.

Grundberg I, Kiflemariam S, Mignardi M, Imgenberg-Kreuz J, Edlund K, Micke P, Sundström M, Sjöblom T, Botling J, Nilsson M.

Oncotarget. 2013 Dec;4(12):2407-18.

40.

Genomic and transcriptional alterations in lung adenocarcinoma in relation to EGFR and KRAS mutation status.

Planck M, Edlund K, Botling J, Micke P, Isaksson S, Staaf J.

PLoS One. 2013 Oct 24;8(10):e78614. doi: 10.1371/journal.pone.0078614. eCollection 2013.

41.

In situ sequencing for RNA analysis in preserved tissue and cells.

Ke R, Mignardi M, Pacureanu A, Svedlund J, Botling J, Wählby C, Nilsson M.

Nat Methods. 2013 Sep;10(9):857-60. doi: 10.1038/nmeth.2563. Epub 2013 Jul 14.

PMID:
23852452
42.

Gene rearrangements in hormone receptor negative breast cancers revealed by mate pair sequencing.

Jiao X, Hooper SD, Djureinovic T, Larsson C, Wärnberg F, Tellgren-Roth C, Botling J, Sjöblom T.

BMC Genomics. 2013 Mar 12;14:165. doi: 10.1186/1471-2164-14-165.

43.

Parallel visualization of multiple protein complexes in individual cells in tumor tissue.

Leuchowius KJ, Clausson CM, Grannas K, Erbilgin Y, Botling J, Zieba A, Landegren U, Söderberg O.

Mol Cell Proteomics. 2013 Jun;12(6):1563-71. doi: 10.1074/mcp.O112.023374. Epub 2013 Feb 22.

44.

The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer.

Lohr M, Edlund K, Botling J, Hammad S, Hellwig B, Othman A, Berglund A, Lambe M, Holmberg L, Ekman S, Bergqvist M, Pontén F, Cadenas C, Marchan R, Hengstler JG, Rahnenführer J, Micke P.

Cancer Lett. 2013 Jun 10;333(2):222-8. doi: 10.1016/j.canlet.2013.01.036. Epub 2013 Jan 28.

PMID:
23370224
45.

Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation.

Botling J, Edlund K, Lohr M, Hellwig B, Holmberg L, Lambe M, Berglund A, Ekman S, Bergqvist M, Pontén F, König A, Fernandes O, Karlsson M, Helenius G, Karlsson C, Rahnenführer J, Hengstler JG, Micke P.

Clin Cancer Res. 2013 Jan 1;19(1):194-204. doi: 10.1158/1078-0432.CCR-12-1139. Epub 2012 Oct 2.

46.

Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma.

Staaf J, Isaksson S, Karlsson A, Jönsson M, Johansson L, Jönsson P, Botling J, Micke P, Baldetorp B, Planck M.

Int J Cancer. 2013 May 1;132(9):2020-31. doi: 10.1002/ijc.27879. Epub 2012 Oct 20.

47.

Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter.

Åkerström T, Crona J, Delgado Verdugo A, Starker LF, Cupisti K, Willenberg HS, Knoefel WT, Saeger W, Feller A, Ip J, Soon P, Anlauf M, Alesina PF, Schmid KW, Decaussin M, Levillain P, Wängberg B, Peix JL, Robinson B, Zedenius J, Bäckdahl M, Caramuta S, Iwen KA, Botling J, Stålberg P, Kraimps JL, Dralle H, Hellman P, Sidhu S, Westin G, Lehnert H, Walz MK, Åkerström G, Carling T, Choi M, Lifton RP, Björklund P.

PLoS One. 2012;7(7):e41926. doi: 10.1371/journal.pone.0041926. Epub 2012 Jul 27.

48.

Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors.

Edlund K, Larsson O, Ameur A, Bunikis I, Gyllensten U, Leroy B, Sundström M, Micke P, Botling J, Soussi T.

Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9551-6. doi: 10.1073/pnas.1200019109. Epub 2012 May 24.

49.

Consistent mutation status within histologically heterogeneous lung cancer lesions.

Mattsson JS, Imgenberg-Kreuz J, Edlund K, Botling J, Micke P.

Histopathology. 2012 Oct;61(4):744-8. doi: 10.1111/j.1365-2559.2012.04245.x.

PMID:
22458769
50.

CD99 is a novel prognostic stromal marker in non-small cell lung cancer.

Edlund K, Lindskog C, Saito A, Berglund A, Pontén F, Göransson-Kultima H, Isaksson A, Jirström K, Planck M, Johansson L, Lambe M, Holmberg L, Nyberg F, Ekman S, Bergqvist M, Landelius P, Lamberg K, Botling J, Ostman A, Micke P.

Int J Cancer. 2012 Nov 15;131(10):2264-73. doi: 10.1002/ijc.27518. Epub 2012 Apr 24.

Supplemental Content

Loading ...
Support Center